Wolvetang Group

AIBN researchers have developed a protein to improve the efficiency and safety of existing gene-editing tool CRISPR-Cas9

AIBN researchers have won vital funding to address the spread of cancer and develop new technology that could fight off the next pandemic.

Researchers from the AIBN have made a significant step towards enabling women with epilepsy safer access to a common anti-seizure medication.

Organoid researchers at the AIBN have won $4.1 million MRFF grant to prove the effectiveness of epilepsy drugs made from spider venom.

A first of its kind brain organoid grown at The University of Queensland has helped researchers identify therapies that reduce the impact of COVID-19 on people with Down syndrome.

For three months Tahmina Tabassum relearned what she knew about industry and entrepreneurship during a placement with biotech Azafaros BV, a whirlwind experience that included a stint at the company’s headquarters in Basel.